UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Tracking Cancer Evolution through the Disease Course.

Bailey, C; Black, JRM; Reading, JL; Litchfield, K; Turajlic, S; McGranahan, N; Jamal-Hanjani, M; (2021) Tracking Cancer Evolution through the Disease Course. Cancer Discovery , 11 (4) pp. 916-932. 10.1158/2159-8290.CD-20-1559. Green open access

[thumbnail of Jamal-Hanjani_cb_cs_stT_racking Cancer Evolution through the Disease Course_v8_jrmb_text_only.pdf]
Preview
Text
Jamal-Hanjani_cb_cs_stT_racking Cancer Evolution through the Disease Course_v8_jrmb_text_only.pdf - Accepted Version

Download (228kB) | Preview

Abstract

During cancer evolution, constituent tumor cells compete under dynamic selection pressures. Phenotypic variation can be observed as intratumor heterogeneity, which is propagated by genome instability leading to mutations, somatic copy-number alterations, and epigenomic changes. TRACERx was set up in 2014 to observe the relationship between intratumor heterogeneity and patient outcome. By integrating multiregion sequencing of primary tumors with longitudinal sampling of a prospectively recruited patient cohort, cancer evolution can be tracked from early- to late-stage disease and through therapy. Here we review some of the key features of the studies and look to the future of the field. SIGNIFICANCE: Cancers evolve and adapt to environmental challenges such as immune surveillance and treatment pressures. The TRACERx studies track cancer evolution in a clinical setting, through primary disease to recurrence. Through multiregion and longitudinal sampling, evolutionary processes have been detailed in the tumor and the immune microenvironment in non-small cell lung cancer and clear-cell renal cell carcinoma. TRACERx has revealed the potential therapeutic utility of targeting clonal neoantigens and ctDNA detection in the adjuvant setting as a minimal residual disease detection tool primed for translation into clinical trials.

Type: Article
Title: Tracking Cancer Evolution through the Disease Course.
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1158/2159-8290.CD-20-1559
Publisher version: https://doi.org/10.1158/2159-8290.CD-20-1559
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10126308
Downloads since deposit
45Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item